ChargePoint Holdings, Inc. (CHPT)
NYSE: CHPT · Real-Time Price · USD
9.19
+0.22 (2.45%)
Jul 31, 2025, 4:00 PM - Market closed
bluebird bio Stock Forecast
Stock Price Forecast
The 8 analysts that cover bluebird bio stock have a consensus rating of "Hold" and an average price target of $29.13, which forecasts a 216.97% increase in the stock price over the next year. The lowest target is $10 and the highest is $60.
Price Target: $29.13 (+216.97%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 5, 2025.
Analyst Ratings
The average analyst rating for bluebird bio stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 8 | 7 | 7 | 7 | 7 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 13 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $20 | Hold | Reiterates | $20 | +117.63% | Jun 5, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 5, 2025 |
| UBS | UBS | Hold Maintains $14 → $13 | Hold | Maintains | $14 → $13 | +41.46% | Apr 17, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $15 → $10 | Strong Sell | Maintains | $15 → $10 | +8.81% | Apr 10, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $80 → $20 | Buy → Hold | Downgrades | $80 → $20 | +117.63% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
428.57M
from 417.08M
Increased by 2.75%
Revenue Next Year
530.68M
from 428.57M
Increased by 23.83%
EPS This Year
-0.22
from -12.80
EPS Next Year
-0.12
from -0.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 479.9M | 589.1M | 857.9M | ||
| Avg | 428.6M | 530.7M | 705.6M | ||
| Low | 379.9M | 456.1M | 559.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.0% | 37.4% | 61.7% | ||
| Avg | 2.8% | 23.8% | 33.0% | ||
| Low | -8.9% | 6.4% | 5.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.17 | -0.06 | -0.01 |
| Avg | -0.22 | -0.12 | -0.09 |
| Low | -0.25 | -0.21 | -0.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.